Predict your next investment

Inveready company logo
Venture Capital
FINANCE | Investment Firms & Funds
inveready.com

See what CB Insights has to offer

Investments

152

Portfolio Exits

18

Funds

14

Partners & Customers

1

About Inveready

Inveready is one of the main groups focused venture capital investment in early stages in Spain, with five investment vehicles. The firm invests in technology-based companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 40 subsidiaries in various sectors leaders.

Inveready Headquarter Location

C/ Dels Cavallers 50

Barcelona, 0834,

Spain

+34 93 180 72 60

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Inveready Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inveready Rank

Latest Inveready News

AOP Health Starts Research for Leukemia Treatment

Aug 1, 2022

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term. August 01, 2022 04:00 ET Vienna, AUSTRIA VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases. Agreement sets basis for new areas of therapy At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.” Development in cooperation with Leukos As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”. About AOP Health The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them. About Leukos Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs. About the Josep Carreras Foundation The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home. About the Josep Carreras Leukaemia Research Institute The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau - Autonomous University of Barcelona (UAB) Campus About Inveready Inveready is a leading alternative asset manager in Spain - investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity - providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com ). Mag Nina Roth, MAS

Inveready Investments

152 Investments

Inveready has made 152 investments. Their latest investment was in Ironchip as part of their Seed VC - II on July 7, 2022.

CBI Logo

Inveready Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/27/2022

Seed VC - II

Ironchip

$2.14M

No

2

7/14/2022

Series A

Twenix

$3.5M

No

2

7/12/2022

Unattributed VC

Createch360

$3.62M

Yes

2

7/11/2022

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

7/7/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/27/2022

7/14/2022

7/12/2022

7/11/2022

7/7/2022

Round

Seed VC - II

Series A

Unattributed VC

Seed VC - II

Seed VC

Company

Ironchip

Twenix

Createch360

Subscribe to see more

Subscribe to see more

Amount

$2.14M

$3.5M

$3.62M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Inveready Portfolio Exits

18 Portfolio Exits

Inveready has 18 portfolio exits. Their latest portfolio exit was Gigas on July 15, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/15/2022

Acq - Fin

$99M

1

6/15/2022

Merger

$99M

2

11/16/2021

Acquired

$99M

6

10/20/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/4/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/15/2022

6/15/2022

11/16/2021

10/20/2021

8/4/2021

Exit

Acq - Fin

Merger

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

6

10

10

Inveready Acquisitions

3 Acquisitions

Inveready acquired 3 companies. Their latest acquisition was True Value Investments on February 28, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/28/2022

$99M

Acq - Fin

2

2/2/2021

Subscribe to see more

$99M

Subscribe to see more

10

3/17/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/28/2022

2/2/2021

3/17/2015

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Inveready Fund History

14 Fund Histories

Inveready has 14 funds, including Inveready Venture Finance III Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/21/2020

Inveready Venture Finance III Fund

$54.8M

2

1/14/2020

Gaea Inversion

Diversified Private Equity

Open

3

6/17/2019

First Capital III

Early-Stage Venture Capital

Closed

$60.6M

2

11/30/2018

Biotech III

Subscribe to see more

Subscribe to see more

$99M

10

7/3/2018

Convertible Finance

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

5/21/2020

1/14/2020

6/17/2019

11/30/2018

7/3/2018

Fund

Inveready Venture Finance III Fund

Gaea Inversion

First Capital III

Biotech III

Convertible Finance

Fund Type

Diversified Private Equity

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$54.8M

$60.6M

$99M

$99M

Sources

2

3

2

10

10

Inveready Partners & Customers

1 Partners and customers

Inveready has 1 strategic partners and customers. Inveready recently partnered with Bit2Me on October 10, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

10/1/2020

Partner

Spain

Date

10/1/2020

Type

Partner

Business Partner

Country

Spain

News Snippet

Sources

Inveready Team

7 Team Members

Inveready has 7 team members, including current Founder, Chief Executive Officer, Josep Ma Echarri.

Name

Work History

Title

Status

Josep Ma Echarri

Founder, Chief Executive Officer

Current

Ana Izquierdo

Founding Partner

Current

Ignacio Fonts

Managing Partner

Current

Josep M Torres

Managing Partner

Current

Carlos Conti

General Partner

Current

Name

Josep Ma Echarri

Ana Izquierdo

Ignacio Fonts

Josep M Torres

Carlos Conti

Work History

Title

Founder, Chief Executive Officer

Founding Partner

Managing Partner

Managing Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.